Table 8.
Polymorphisms within non-coding RNAs and risk of neuroblastoma.
| lncRNA/miRNA | Number of clinical samples | SNP ID | Nucleotide change | OR (95%CI) | p-value | Description | Reference |
|---|---|---|---|---|---|---|---|
| LINC00673 | 700 cases and 1516 controls | rs11655237 | C>T | 1.58 (1.06–2.35) | 0.024 | Patients with the T allele are considerably more prone to develop NB. A substantial association exists between rs11655237 CT/TT and NB risk in subgroups of males, adrenal gland tumors, and patients with stage IV disease. | (137) |
| H19 | 393 NB patients and 812 healthy controls | rs2839698 | G>A | – | – | Separated and combined analyses indicated no associations between these polymorphisms and NB susceptibility. Only female children with rs3024270 GG genotypes had a raised NB risk. | (138) |
| rs3024270 | C>G | 1.61 (1.04-2.50) | 0.032 | ||||
| rs217727 | G>A | – | – | ||||
| MEG3 | 392 NB children and 783 controls | rs7158663 | G>A | – | – | Patients with rs4081134 AG/AA genotypes were significantly prone to develop NB among subgroups with age >18 months and stage III+IV. Carriers of these two polymorphisms were more prone to NB. These associations were found in children more than 18 months and with clinical stages of III+IV. | (142) |
| rs4081134 | G>A | NB developments: 1.36 (1.01-1.84), clinical stage III+IV: 1.47 (1.08-1.99) | 0.042 and 0.014 respectively | ||||
| CAC15-S | 250 primary NB, 20 NB cell lines | rs9295534 | T>A | 1.63 (1.4-1.89) | 3.51×10-12 | This polymorphism is located upstream of CASC15-S and spans regulatory chromatin and dense transcription factor binding site. This genomic area has an enhancer-like activity that is disturbed by NB risk allele. | (126) |
| HOTAIR | 393 NB and 812 healthy controls | rs12826786 | C>T | 1.98 (1.14-3.42) | 0.015 | These polymorphisms are markedly associated with increased NB risk. In stratification analyses, these associations are more dominant in females and among patients with tumors in the retroperitoneal or mediastinal tumors. | (140) |
| rs874945 | C>T | 1.91 (1.10-3.32) | 0.022 | ||||
| rs1899663 | C>A | 1.87 (1.05-3.32) | 0.033 | ||||
| LINC00673 | 393 NB and 812 healthy controls | rs11655237 | C>T | NB risk: 1.51 (1.06-2.14), stage IV disease: 1.60 (1.12-2.30) | 0.021 and 0.011 respectively | Carriers of rs11655237 T allele are prone to NB. Associations were found in patients with adrenal gland tumors and stage IV disease. | (143) |
| uc003opf.1 | 275 patients and 531 controls | rs11752942 | A>G | 0.74 (055-0.99) | 0.045 | rs11752942 G allele is negatively related to NB risk and is more prominent in females, subjects with tumors in the mediastinum or early-stage. Besides, rs11752942 G is associated with deceased levels of LRFN2 transcripts. | (144) |
| CASC15 and NBAT1 | 36 NB patients and NB cell lines | rs6939340 | A>G | – | – | This polymorphism results in lowered expression of CASC15 and NBAT1. | (127) |
| NBAT1 | 51 high-risk primary tumors and NB cell lines | rs6939340 | A>G | – | P < 0.05 | Lowered NBAT-1 expression in high-risk tumors relates to rs6939340. | (85) |
| Lnc-LAMC2–1:1 | 393 NB and 812 healthy cases | rs2147578 | C>G | 1.33 (1.01-1.75) | 0.045 | rs2147578 rises NB susceptibility. Children under 18 months and females have increased NB risk. | (145) |
| miR-34b/c | 162 NB and 270 healthy controls | rs4938723 | T>C | 0.49 (0.33-0.73) | 0.0005 | rs4938723 diminishes NB risk. The stratified analysis demonstrates that rs4938723 TC/CC carriers are less prone to NB. Such association was found in both age subgroups, both sexes as well as all tumor sites and stages. | (141) |